Ascendis Pharma

Historical price data

Ascendis Pharma is a mission-driven biotech focused on developing novel therapeutics for rare endocrine diseases and oncology using its proprietary TransCon (transient conjugation) platform. The company has achieved commercial success with its first product, Skytrofa (TransCon hGH), and is advancing a deep pipeline, including late-stage candidates for achondroplasia and hypoparathyroidism. Its strategy combines internal development with strategic geographic partnerships to maximize the global potential of its platform, aiming to build a leading, fully integrated biopharmaceutical company.

TransCon (Transient Conjugation) is a prodrug platform that temporarily links an inert carrier to an unmodified parent drug, enabling controlled, extended release of the active drug to improve dosing convenience and therapeutic profile.